[Corrections] Correction to Lancet Oncol 2023; 24: 483–95

February, 02, 2024 | Select Oncology Journal Articles

Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023; 24: 483–95—In this Article, errors in figure 2 have been corrected, a footnote missing from table 2 has been added, and the appendix has been corrected. These corrections have been made to the online versions as of Feb 26, 2024.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy